author-photo

Frederick B. Hagemeister

University of Texas MD Anderson Cancer Center

59

Papers

2266

Citations

Citation Trend

Filter By

Papers (43) Sort By

Journal Conference Others

Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.

2020 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (65)
Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

2020 Oncologist
Show All
- Source
- Cite
- Save
Citations (3)
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma

2019 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (34)
Erratum to: Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma: Low-dose radiotherapy for adnexal b-cell lymphoma (Head & Neck, (2017), 39, 6, (1095-1100), 10.1002/hed.24717)

2019 Head and Neck-journal for The Sciences and Specialties of The Head and Neck
Show All
- Source
- Cite
- Save
Citations (1)
Obinutuzumab Treatment of Follicular Lymphoma.

2017 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (4)
Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?

2017 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (8)
Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplant (ASCT) in Hodgkin's Lymphoma Patients at High Risk of Post-Transplant Recurrence—Comparison with a Concurrent Matched Cohort

2017 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)